Inflammation Research

, Volume 63, Issue 10, pp 873–883 | Cite as

Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis

  • Sumei Sha
  • Bin Xu
  • Xiangyun Kong
  • Ni Wei
  • Jian Liu
  • Kaichun Wu
Original Research Paper



To analyze the in vivo effect of Escherichia coli Nissle 1917 (EcN) with different courses and different doses to Sprague–Dawley rats with trinitrobenzene sulfonic acid (TNBS)-induced colitis.


The probiotic was orally administered with different courses of treatment (with or without pre-administration) and different doses (107–109 CFU/day) to Sprague–Dawley rats with TNBS-induced colitis. Therapeutic effects, levels of cytokine in serum, mRNA and protein expression were analyzed.


Oral EcN administration after TNBS-induced improved colitis dose dependently. In parallel, a reduction of disease activity index and colonic MPO activity together with a decreased level of TNF-α and a trend of increased IL-10 expression was detected. Pre-administration of 10CFU/day EcN to TNBS-treated rats resulted in a significant protection against inflammatory response and colons isolated from these rats exhibited a more pronounced expression of ZO-1 than the other groups. In the group of pre-administration of 10CFU/day, the condition was not improved but deteriorated.


This study convincingly demonstrates that pre-administration of probiotic EcN with low dose is able to protect colitis of rats and mediate up-regulation of ZO-1 expression, but long-term of high-dose EcN may do harm to colitis.


Probiotic Trinitrobenzene sulfonic acid Myeloperoxidase Tumor necrosis factor-alpha Interleukin-10 



This study was supported by grants from the National Scientific Support Project (nos. 20100202, 02012BAI06B03 and BSW11J013), National Natural Science Foundation of China (Nos. 81322037 and 81370504) and National Excellent Doctoral Dissertation of PR China (No. 201182).

Conflict of interest

There are no conflicts of interest to disclose in this paper.


  1. 1.
    Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2–25 quiz S26.CrossRefPubMedGoogle Scholar
  2. 2.
    Wang Y, Ouyang Q. Ulcerative colitis in China: retrospective analysis of 3,100 hospitalized patients. J Gastroenterol Hepatol. 2007;22:1450–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–17.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Huys G, Vanhoutte T, Vandamme P. Application of sequence-dependent electrophoresis fingerprinting in exploring biodiversity and population dynamics of human intestinal microbiota: what can be revealed? Interdiscip Perspect Infect Dis. 2008;2008:597603.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Lefkovitz AL, Zarowitz BJ. It’s a microscopic world after all: prebiotics, probiotics, and synbiotics. Geriatr Nurs. 2013;34:323–5.CrossRefPubMedGoogle Scholar
  6. 6.
    McNabb B, Isakow W. Probiotics for the prevention of nosocomial pneumonia: current evidence and opinions. Curr Opin Pulm Med. 2008;14:168–75.CrossRefPubMedGoogle Scholar
  7. 7.
    Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle, a novel effect of a probiotic bacterium. Infect Immun. 1917;2004(72):5750–8.Google Scholar
  8. 8.
    Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol. 2000;66:2578–88.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, et al. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol. 2002;97:1182–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab. 1996;40:137–45.CrossRefPubMedGoogle Scholar
  11. 11.
    Schultz M, Linde HJ, Lehn N, Zimmermann K, Grossmann J, Falk W, et al. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res. 2003;70:165–73.CrossRefPubMedGoogle Scholar
  12. 12.
    Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999;276:G941–50.PubMedGoogle Scholar
  13. 13.
    Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580–91.CrossRefPubMedGoogle Scholar
  14. 14.
    Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, Elze M, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr. 2007;166:311–8.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Henker J, Laass MW, Blokhin BM, Maydannik VG, Bolbot YK, Elze M, et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J. 2008;27:494–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol. 2003;15:313–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Schultz M. Clinical use of E. coli Nissle, in inflammatory bowel disease. Inflamm Bowel Dis. 1917;2008(14):1012–8.Google Scholar
  18. 18.
    Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–23.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Hoffmann JC, Zeitz M, Bischoff SC, Brambs HJ, Bruch HP, Buhr HJ, et al. Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of digestive and metabolic diseases and the competence network on inflammatory bowel disease. Z Gastroenterol. 2004;42:979–83.CrossRefPubMedGoogle Scholar
  20. 20.
    Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol. 1997;25:653–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Gronbach K, Eberle U, Muller M, Olschlager TA, Dobrindt U, Leithauser F, et al. Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. Infect Immun. 2010;78:3036–46.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Behnsen J, Deriu E, Sassone-Corsi M, Raffatellu M. Probiotics: properties, examples, and specific applications. Cold Spring Harb Perspect Med. 2013;3:a010074.CrossRefPubMedGoogle Scholar
  23. 23.
    Camuesco D, Comalada M, Rodriguez-Cabezas ME, Nieto A, Lorente MD, Concha A, et al. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol. 2004;143:908–18.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Bell CJ, Gall DG, Wallace JL. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol. 1995;268:G622–30.PubMedGoogle Scholar
  25. 25.
    Arribas B, Rodriguez-Cabezas ME, Camuesco D, Comalada M, Bailon E, Utrilla P, et al. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol. 2009;157:1024–33.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol. 2004;40:223–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620–33.CrossRefPubMedGoogle Scholar
  28. 28.
    Scholmerich J. Inflammatory bowel disease: pandora’s box, present and future. Ann N Y Acad Sci. 2006;1072:365–78.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Basel 2014

Authors and Affiliations

  • Sumei Sha
    • 1
  • Bin Xu
    • 1
    • 2
  • Xiangyun Kong
    • 3
  • Ni Wei
    • 1
  • Jian Liu
    • 1
  • Kaichun Wu
    • 1
  1. 1.State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive DiseasesThe Fourth Military Medical UniversityXi’anPeople’s Republic of China
  2. 2.No. 174 Hospital of People’s Liberation ArmyXiamenPeople’s Republic of China
  3. 3.Department of GastroenterologyXi’an No.1 HospitalXi’anPeople’s Republic of China

Personalised recommendations